Home  /  The AO Blog  /  Longevity

Mounjaro in Penang: What a Clinic Here Is Legally Allowed to Tell You.

If you searched for a weight-management injection by brand name and landed here expecting availability and a price, this page will not give you either, and the reason is the law rather than coyness. Dr. Daniel Chong on what Malaysian advertising rules actually say, why they exist, and what you can usefully do instead.

Book a consultation Longevity Clinic

Written and medically reviewed by Dr. Daniel Chong. Last reviewed 2026-11-18. 10 min

By Dr. Daniel Chong · Human Performance and Longevity, AOKLINIK

Most people who arrive at this page typed a brand name and a city into a search box. They wanted three things: whether it is available here, what it costs, and how to get it.

This page will not give you any of those, and I want to explain why properly rather than leave you assuming we are being evasive.

It is not coyness and it is not a sales technique. Malaysian law places prescription medicines almost entirely outside what a clinic may say to the public, and a website article is explicitly treated as an advertisement. A page offering you a prescription medicine by brand, with a price and a booking link, is not a bolder clinic. It is a clinic operating outside the rules, and that is worth knowing before you choose where to go.

What this page can do is explain the rule, explain why it is protective rather than merely bureaucratic, and tell you what is actually useful to do next.

The short version

  • Malaysian clinics may not advertise prescription medicines to the public. That covers brand names, availability and price, on a website as much as on a billboard.
  • The rule is not about weight management specifically. It applies to prescription medicines as a class, and separately and more strictly to a listed set of diseases for which no public advertisement is permitted at all.
  • A clinic publishing a price list for a prescription medicine is not giving you better service. It is accepting a risk on your behalf that you were not asked about.
  • Nothing stops a doctor discussing any of this with you in a consultation. The restriction is on advertising to the public, not on clinical conversation.
  • The thing worth avoiding is unsupervised supply, which is widely available online and is where the real harm in this category happens.
  • If you want the medicine, the route is an assessment. Not because we are gatekeeping, but because the assessment is what makes the treatment reasonable rather than merely available.

What the law actually says

Two instruments matter here, and it is worth seeing them rather than taking my summary on trust.

The Medicines (Advertisement and Sale) Act 1956. Section 3 prohibits publishing any advertisement presenting something as a remedy for a listed set of conditions. That Schedule is specific and it is not short: kidney and heart disease, diabetes, epilepsy, paralysis, tuberculosis, asthma, cancer, hypertension, mental disorder and others. For those conditions there is no approval process to apply for. The advertisement is simply not permitted.

Section 4A goes further and covers advertisements referring to a skill or service for treating an ailment where the advertisement invites the reader to seek the advertiser's advice. Private clinics can advertise, but only with approval from the Medicine Advertisements Board, which is where the KKLIU numbers you see on Malaysian healthcare advertising come from.

The Ministry of Health's guideline on advertising medicines to the general public. Two parts of it are decisive. First, it states that no approval shall be given for poisons specified in the First Schedule, which is where prescription medicines sit, apart from a short list of exemptions that does not cover this category. Second, it defines an advertisement broadly enough to include "website and other internet materials", and it explicitly names articles and advertorials.

Put those together. A prescription medicine cannot be advertised to the public, a clinic website article counts as an advertisement, and for the listed diseases no approval exists at any price.

Why I think the rule is a good one, even though it is inconvenient for us

It would plainly be easier commercially to publish a brand, a price and a button. I still think the restriction is correct, for three reasons that have nothing to do with compliance.

Price is the wrong first question and advertising makes it the first question. Nobody sensibly chooses a prescription medicine the way they choose a phone plan. Whether a particular medicine is appropriate depends on your history, your other conditions, your other medicines and what you are actually trying to change. A price list invites you to skip all of that, and plenty of people do.

Advertising a medicine creates demand for it specifically. Patients then arrive having already decided, which makes a genuine assessment harder rather than easier. A consultation where the conclusion is "not this, and here is why" is a much more difficult conversation when the patient has spent two weeks reading about the thing they came for.

It would place us in competition on exactly the wrong axis. If the public comparison between clinics is price per vial, the clinic that wins is the one supplying least supervision, or supplying from least reliable sources. That is a race that ends badly for patients, and the restriction is part of what keeps it from starting.

The thing actually worth worrying about

Not the rule. The supply.

Medicines in this category are available online, through social media sellers, through informal importers and through people who are not clinicians. Demand has outrun legitimate supply in several markets at various points, and that gap is exactly where falsified product appears. Regulators in several countries have issued warnings about falsified pens in this class, and the pattern is familiar from every other category where demand has outstripped supply.

Three things make this particular category worse than most.

It is injected, so a falsified or mishandled product goes straight into tissue with no opportunity to reconsider.

It requires a cold chain. Even genuine product, stored or transported badly, may not be what the label says it is by the time it reaches you, and nothing about the pen will tell you.

It is dose-escalated over months. This is not a single treatment with a single decision. It is an ongoing one with scheduled changes, side effects that need managing, and a point at which continuing or stopping has to be decided on evidence. That is a clinical relationship, not a purchase.

If you take one thing from this page, make it this: the risk in this category is not the medicine, it is obtaining it outside a supervised relationship.

What actually happens in an assessment

Since I cannot tell you what we stock or what it costs, here is the more useful thing, which is what the process consists of. None of it is unique to us, and you should expect it anywhere.

A baseline that can be measured against. Weight is the least informative number in the room. Body composition, waist, blood pressure, a lipid panel including ApoB, markers of glucose handling and liver function, and a medication and medical history. Treatment started without a baseline cannot be evaluated later, which is how people end up continuing indefinitely by default.

An indication, not a wish. There is a clinical situation for which a given treatment has trial evidence in people like you, and there is a desire to accelerate progress. They are not the same, and only the first is a reason to prescribe.

A discussion of what you are giving up. Weight-lowering treatment in this class causes meaningful loss of lean tissue alongside fat unless protein intake and resistance training are actively managed. That lean tissue loss works directly against the metabolic goal, which is the thing most of the enthusiastic coverage omits. We have written about that at length in our protocol notes and in a guide to protein when you eat Malaysian food.

A monitoring schedule. Scheduled review, scheduled repeat measurement, and an agreed point at which the treatment is assessed rather than simply renewed.

An exit plan, discussed at the start. What happens when you stop is a question that deserves an answer before you begin, not after.

And the possibility that the answer is no. Contraindications exist, and so do situations where the gap between where you are and where you need to be is one that lifestyle change can close. A clinic that never declines is not being generous.

What to ask, including of us

1. Who is assessing me, and are they a registered medical practitioner?

2. What is being measured before anything starts, and when is it measured again?

3. What is the indication in my case, stated plainly?

4. What are the side effects I should expect, and which ones mean I should stop and call?

5. How is lean tissue loss being managed, specifically?

6. What is the plan for stopping, and what happens afterwards?

7. Is anyone here paid according to what I buy?

8. Where does the medicine come from, and can you account for the cold chain?

A clinic with a proper process answers all eight without hesitation. A clinic that answers the price question quickly and the other seven slowly has told you where its attention is.

The short version, again

You came looking for availability and a price, and the honest answer is that no Malaysian clinic may publish either for a prescription medicine, this one included. Pages that do are not better informed. They are taking a risk you were not consulted about.

The useful version of what you were looking for is an assessment: a baseline that can be measured against, an indication rather than a wish, a plan for lean tissue, a monitoring schedule and an agreed exit. That conversation can cover anything, including the thing you searched for.

Book a metabolic assessment

Bring whatever you have already read, including the things you read on social media. It is far better to discuss it than to leave it out.

Book a consultation at AOKLINIK Penang.

Book your consultation

References

1. Medicines (Advertisement and Sale) Act 1956 (Act 290, revised 1983), sections 3, 4A and 4B, and the Schedule of conditions for which advertisement to the public is prohibited.

2. Ministry of Health Malaysia, Pharmaceutical Services Programme. Guideline on Advertising of Medicines and Medicinal Products to the General Public, including the definition of an advertisement as covering website and internet materials, and the provision that no approval shall be given for First Schedule poisons.

3. Medicine Advertisements Board (Lembaga Iklan Ubat), Ministry of Health Malaysia, on the KKLIU approval process for healthcare advertising.

Frequently asked questions

What I can tell you is that weight management with medical supervision is part of what the clinic does, and that any medicine involved is a prescription decision made in a consultation after an assessment. What I cannot tell you on a public page is which medicines, whether a particular one is held, or what anything costs, because that is advertising a prescription medicine to the public and it is not permitted.

I cannot speak to another clinic's arrangements. I can tell you what the Act and the Ministry guideline say, which is set out above, and suggest you read them yourself. They are public documents.

Related. A KKLIU number shows that an advertisement has been approved by the Medicine Advertisements Board. The point about prescription medicines is that for this category approval is not available, so there is no number that would make such an advertisement permissible.

Because you searched for it, and telling you plainly why the answer is not here seemed more useful than letting you conclude we do not do this work. The brand appears here in the context of explaining a restriction, not as an offer.

You can. I would urge you not to. The product may not be what the label says, the cold chain is unverifiable, the dose escalation is where most of the avoidable side effects occur, and nobody is measuring whether it is working. If you have already started this way, please see a doctor rather than stopping the conversation out of embarrassment. Nobody will tell you off.

Then say so at the start, and the assessment is still worth having. A good proportion of what moves these markers is not pharmacological, and the measurement is what tells you whether it is working. There is a longer piece on what a metabolic reset actually involves.

No, and deliberately. Diabetes is one of the conditions listed in the Schedule to the 1956 Act, for which no public advertisement is permitted at all. Anything on that subject belongs in a consultation with your own doctor. ---

Book a consultation Longevity Clinic Published prices
Book Your Consultation
Find Your TreatmentBook Now